HK1177952A1 - Compositions for vaccinating against hsv-2 hsv-2 - Google Patents

Compositions for vaccinating against hsv-2 hsv-2

Info

Publication number
HK1177952A1
HK1177952A1 HK13105731.8A HK13105731A HK1177952A1 HK 1177952 A1 HK1177952 A1 HK 1177952A1 HK 13105731 A HK13105731 A HK 13105731A HK 1177952 A1 HK1177952 A1 HK 1177952A1
Authority
HK
Hong Kong
Prior art keywords
hsv
compositions
vaccinating against
vaccinating
against hsv
Prior art date
Application number
HK13105731.8A
Other languages
English (en)
Chinese (zh)
Inventor
Michal Margalith
Adrian Vilalta
David M Koelle
Lichun Dong
Original Assignee
Vical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vical Inc filed Critical Vical Inc
Publication of HK1177952A1 publication Critical patent/HK1177952A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HK13105731.8A 2006-07-20 2013-05-14 Compositions for vaccinating against hsv-2 hsv-2 HK1177952A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80791106P 2006-07-20 2006-07-20
PCT/US2007/074045 WO2008011609A2 (en) 2006-07-20 2007-07-20 Compositions and methods for vaccinating against hsv-2

Publications (1)

Publication Number Publication Date
HK1177952A1 true HK1177952A1 (en) 2013-08-30

Family

ID=38851640

Family Applications (1)

Application Number Title Priority Date Filing Date
HK13105731.8A HK1177952A1 (en) 2006-07-20 2013-05-14 Compositions for vaccinating against hsv-2 hsv-2

Country Status (7)

Country Link
US (15) US7628993B2 (ja)
EP (1) EP2521786B1 (ja)
JP (3) JP5872755B2 (ja)
AU (1) AU2007275047A1 (ja)
CA (1) CA2658484A1 (ja)
HK (1) HK1177952A1 (ja)
WO (1) WO2008011609A2 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9912671A (pt) * 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
WO2009049351A1 (en) * 2007-10-15 2009-04-23 The University Of Queensland Construct system and uses therefor
WO2010002418A2 (en) * 2008-07-01 2010-01-07 The Johns Hopkins University Quick-dissolving oral thin film for targeted delivery of therapeutic agents
EP2389362B1 (en) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
WO2010115172A2 (en) 2009-04-03 2010-10-07 University Of Washington Antigenic peptide of hsv-2 and methods for using same
RU2585961C9 (ru) 2009-05-22 2016-12-27 Дженосеа Биосайенсиз Инк. Вакцины против вируса простого герпеса 2 типа: композиции и способы запуска иммунного ответа
CN102639496B (zh) 2009-09-25 2014-10-29 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
EP2486002B1 (en) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
BR112012026694A2 (pt) 2010-04-19 2016-07-12 Oryzon Genomics Sa inibidores da desmetilase específica para lisina 1 e seu uso
WO2012013728A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
MX2013001613A (es) 2010-08-09 2013-04-22 Cyvax Inc Métodos y composiciones para prevenir una afección.
HUE061275T2 (hu) * 2010-08-31 2023-06-28 Glaxosmithkline Biologicals Sa Kis liposzómák immunogént kódoló RNS bejuttatására
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
WO2012072713A2 (en) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
JP6099573B2 (ja) * 2011-01-31 2017-03-22 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 新規なヘルペス抗原をコードする核酸分子、それを含むワクチン及びその使用方法
WO2012107498A1 (en) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Lysine demethylase inhibitors for myeloproliferative disorders
EP2502631A1 (en) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immune suppressor and its use
WO2013006401A2 (en) * 2011-07-01 2013-01-10 Immport Therapeutics, Inc. Methods and compositions of protein antigens for the diagnosis and treatment of herpes simplex viruses type 1 and 2
BR112014008167B1 (pt) 2011-10-05 2022-05-24 Genvec Inc Adenovírus ou vetor adenoviral e composição os compreendendo
US9629906B2 (en) 2011-10-05 2017-04-25 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
BR112014008284A2 (pt) 2011-10-05 2020-10-27 Genvec Inc. adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso
RU2681211C2 (ru) 2011-10-20 2019-03-05 Оризон Дженомикс С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
SG11201401066PA (en) 2011-10-20 2014-10-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
CA2885693C (en) 2011-11-23 2020-07-28 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
US20140363469A1 (en) * 2012-01-19 2014-12-11 Alnylam Pharmaceuticals, Inc. Viral attenuation and vaccine production
EP2850431B1 (en) 2012-05-16 2018-04-18 Immune Design Corp. Vaccines for hsv-2
EP2855511B1 (en) 2012-05-29 2019-07-24 GenVec, Inc. Herpes simplex virus vaccine
US9566325B2 (en) 2013-01-07 2017-02-14 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type-2 infections
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP6881813B2 (ja) 2014-04-23 2021-06-02 モデルナティーエックス， インコーポレイテッド 核酸ワクチン
CN107810009A (zh) 2015-05-15 2018-03-16 库瑞瓦格股份公司 涉及施用至少一种mRNA构建体的初免‑加强方案
JP2018536023A (ja) * 2015-10-22 2018-12-06 モデルナティーエックス， インコーポレイテッド 単純ヘルペスウイルスワクチン
WO2018064232A1 (en) 2016-09-28 2018-04-05 Genocea Biosciences, Inc. Methods and compositions for treating herpes
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
MA49463A (fr) * 2017-04-26 2021-05-05 Modernatx Inc Vaccin contre le virus de l'herpès simplex
CN111246854A (zh) * 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
CN110343707B (zh) * 2019-05-30 2021-06-15 中国科学院生物物理研究所 基于乙肝核心抗原的hsv分型用蛋白、试剂盒及方法和应用
CN115227674B (zh) * 2022-08-05 2023-07-04 武汉滨会生物科技股份有限公司 包封的溶瘤病毒遗传物质及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5147055A (en) * 1991-09-04 1992-09-15 Gerry Baby Products Company Diaper container
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
GB9401333D0 (en) * 1994-01-25 1994-03-23 Medical Res Council Herpes virus pre-(viral dna replication) particles (preps)
US5641665A (en) 1994-11-28 1997-06-24 Vical Incorporated Plasmids suitable for IL-2 expression
US5654174A (en) * 1995-07-07 1997-08-05 Competitive Technologies, Inc. Herpes simplex virus glycoprotein D variants
US5972666A (en) * 1996-07-26 1999-10-26 G. D. Searle & Co. Assembly-deficient herpesvirus vaccine
US20020045594A1 (en) * 1997-02-14 2002-04-18 Merck & Co., Inc. Polynucleotide vaccine formulations
BR9912671A (pt) 1998-08-07 2001-05-02 Univ Washington Antìgenos imunológicos para o vìrus de herpes simples e métodos para sua utilização
US6586409B1 (en) * 1999-03-26 2003-07-01 Vical Incorporated Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
JP4932086B2 (ja) * 1999-04-08 2012-05-16 インターセル ユーエスエイ、インコーポレイテッド 経皮的免疫のための乾燥製剤
CA2379623C (en) 1999-09-30 2014-09-09 University Of Washington Immunologically significant herpes simplex virus antigens
NZ538837A (en) * 1999-11-03 2007-02-23 Powderject Vaccines Inc DNA-vaccines based on constructs derived from the genomes of human and animal pathogens
US20030165819A1 (en) * 2000-06-29 2003-09-04 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
DE10035555A1 (de) * 2000-07-21 2002-01-31 Mann & Hummel Filter Auswechselbare Filterpatrone mit Stützkörper bzw. Flüssigkeitsfilter mit eben dieser Filterpatrone
US6867000B2 (en) * 2000-12-07 2005-03-15 Wyeth Holdings Corporation Method of enhancing immune responses to herpes
CA2489019A1 (en) * 2001-06-15 2002-12-27 Nordic Vaccine Technology A/S Therapeutical vaccination
WO2003011893A2 (en) 2001-07-31 2003-02-13 University Of Washington Immunologically significant herpes simplex virus antigens and methods for using same
EP1420065A4 (en) * 2001-08-02 2005-03-09 Anges Mg Inc PROCESS FOR PRODUCING INACTIVE VIRAL ENVELOPES
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
WO2003104400A2 (en) 2002-06-07 2003-12-18 Rmf Dictagene S.A. Secretory signal sequences and uses thereof
EP2011510B1 (en) 2002-07-18 2011-01-12 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
EP1394258A1 (en) * 2002-08-30 2004-03-03 Geneart GmbH Non-human herpesviruses as vectors
US20050130132A1 (en) * 2002-09-06 2005-06-16 Day Craig H. Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
WO2005012545A2 (en) * 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
US20070274997A1 (en) * 2003-07-25 2007-11-29 Anthony Simmons Compositions and Methods for Herpes Simplex Prophylaxis and Treatment
CN1889963A (zh) * 2003-10-10 2007-01-03 宝德杰克特疫苗有限公司 方法
AU2005248361B2 (en) 2004-05-18 2010-03-11 Vical Incorporated Influenza virus vaccine composition and methods of use
US7288514B2 (en) * 2005-04-14 2007-10-30 The Clorox Company Polymer-fluorosurfactant associative complexes
CA2658484A1 (en) * 2006-07-20 2008-01-24 Vical Incorporated Compositions and methods for vaccinating against hsv-2
JP2008131867A (ja) * 2006-11-27 2008-06-12 Univ Of Tokyo ウイルス粒子の３つのコンポーネントを異なる蛍光タンパク質で標識した組換えウイルス
US20090004203A1 (en) 2007-05-29 2009-01-01 Vical Incorporated Methods of treating measles infectious disease in mammals

Also Published As

Publication number Publication date
US20150010596A1 (en) 2015-01-08
JP2009544289A (ja) 2009-12-17
US20140370055A1 (en) 2014-12-18
US20100040651A1 (en) 2010-02-18
US8852611B2 (en) 2014-10-07
US20130273107A1 (en) 2013-10-17
US8834894B2 (en) 2014-09-16
US20120328658A1 (en) 2012-12-27
US7628993B2 (en) 2009-12-08
AU2007275047A8 (en) 2009-03-12
US8263087B2 (en) 2012-09-11
US8852610B2 (en) 2014-10-07
US7879339B2 (en) 2011-02-01
US8828408B2 (en) 2014-09-09
US8840903B2 (en) 2014-09-23
EP2521786B1 (en) 2015-06-24
CA2658484A1 (en) 2008-01-24
EP2521786A2 (en) 2012-11-14
US20150010597A1 (en) 2015-01-08
US9161973B2 (en) 2015-10-20
US20100160418A1 (en) 2010-06-24
WO2008011609A2 (en) 2008-01-24
US9205146B2 (en) 2015-12-08
US8840904B2 (en) 2014-09-23
JP5872755B2 (ja) 2016-03-01
US20130273108A1 (en) 2013-10-17
US20100160419A1 (en) 2010-06-24
WO2008011609A3 (en) 2008-07-24
JP2016052322A (ja) 2016-04-14
AU2007275047A1 (en) 2008-01-24
JP2013138680A (ja) 2013-07-18
US8293248B2 (en) 2012-10-23
US20130202640A1 (en) 2013-08-08
US20100158949A1 (en) 2010-06-24
US7935352B2 (en) 2011-05-03
US20150030631A1 (en) 2015-01-29
US20080102087A1 (en) 2008-05-01
US20120328656A1 (en) 2012-12-27
US20120328657A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
HK1177952A1 (en) Compositions for vaccinating against hsv-2 hsv-2
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
GB0606876D0 (en) Compounds
GB0605786D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
GB0605784D0 (en) Compounds
GB0605785D0 (en) Compounds
EP2082022A4 (en) COMPOUNDS
EP2059496A4 (en) acetylene
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0602042D0 (en) Compounds
EP1973905A4 (en) COMPOUNDS
AP2009004767A0 (en) Cubstituted azolin-2-yl-amino compounds
EP2016069A4 (en) BISPYRIDINIUMVERBINDUNGEN
GB0612425D0 (en) Compounds
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
HU0600193V0 (en) Latch-cover for water-network
GB0600426D0 (en) Compounds
GB0603133D0 (en) Compounds
GB0602451D0 (en) Compounds
GB0602454D0 (en) Compounds
GB0602455D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190723